Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
Metagenomi, Inc. (NASDAQ: MGX) had its price target raised by analysts at HC Wainwright from $7.00 to $14.00. They now have a "buy" rating on the stock.
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
Metagenomi, Inc. Class Action: Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024 - MGX
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Metagenomi, Inc. (MGX) Shareholders